Alzheimer's Clinical Trial Results, Sadly Running True To Form [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Novo Nordisk (NVO) recently reported that semaglutide (the company's GLP-1 agonist drug) failed in two Alzheimer's trials. Studies of thousands of patients with early cognitive impairment who took an oral form of semaglutide (Rybelsus) did not show improvements in mental function as compared to placebo. J&J's (JNJ) shot at an anti-tau antibody (posdinemab) has also failed its pivotal trial, with no efficacy seen in slowing the disease at the two-year mark. gorodenkoff/iStock via Getty Images Originally published on November 25, 2025 There have been some interesting failures recently in Alzheimer's trials. As long-time readers will know, I consider basically all Alzheimer's drug trials to have failed to one degree or another, and particularly This article was written by Quick Insights Semaglutide failed to improve cognitive function versus placebo, despite showing improvement in unspecified Alzheimer's biomarkers. NVO's stock declined on the news, reflecting investor d
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]MSNBC.com
- Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website